

Special Issue

Antifungal Resistance and Emerging Therapeutic Options

Message from the Guest Editor

Dear colleagues, The increased use of antifungal agents for the treatment of invasive fungal diseases results in antifungal resistance worldwide. Resistance to triazoles has been one of the major problems in invasive candidiasis and candidemia. The prevalence of fluconazole-resistance *Candida tropicalis* and other *Candida* species is increasing in some particular areas. Furthermore, outbreaks of *Candida auris* have been reported and hindered the infection control process. Novel antifungal agents with new mechanisms are emerging. Antifungal targets are not only focused on membrane-associated ergosterol or cell-wall-associated beta-D-glucan, but also on the fungal enzymes used for various cellular functions. These are the new paradigm of antifungal therapy for infection caused by resistant fungi. This Special Issue will publish papers focusing on fungal infection related to antifungal resistance and novel antifungal agents that can potentially be used to combat these resistant fungal pathogens. **Keywords:** antifungal resistance; new antifungal; azole-resistant; invasive fungal diseases; *Candida*; *Aspergillus*; mold infection; resistance mechanism

Guest Editor

Dr. Methee Chayakulkeeree

Division of Infectious Diseases and Tropical Medicine of the Department of Medicine of the Faculty of Medicine Siriraj Hospital, Mahidol University in Bangkok, Bangkok, Thailand

Deadline for manuscript submissions

closed (30 November 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/149761

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)